Review article: acute severe ulcerative colitis – evidence‐based consensus statements

Chen, J.-H.; Andrews, Jane M.; Kariyawasam, Viraj C.; Moran, Neil; Gounder, Pav; Collins, G; Walsh, Alissa J.; Connor, Susan J.; Lee, T. W. T.; Koh, Cherry; Chang, Jeff; Paramsothy, Sudarshan; Tattersall, Stephen; Lemberg, Daniel A.; Radford‐Smith, Graham; Lawrance, Ian C.; McLachlan, A.; Moore, Gregory Thomas Charles; Corte, Crispin; Katelaris, Peter; Leong, Rupert W.

doi:10.1111/apt.13670

Cited by 68 publications

(76 citation statements)

References 215 publications

(261 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We have no access to data on in‐patient prescription and are thus unable to exclude the possible effect of thromboprophylaxis. However since in‐patient thromboprophylaxis is part of the standard care in both IBD‐related surgical and non‐surgical admissions, the differences we have found are unlikely to be attributable to this practice . Thus, our finding of high risk of venous thromboembolism in the first 6 weeks after leaving hospital following surgery for inflammatory bowel disease is valid notwithstanding this limitation of our data.…”

Section: Discussionmentioning

confidence: 62%

The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity

Chu

Grainge

Card

2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

Summary Background Inflammatory bowel disease (IBD) increases the risk of venous thromboembolism. Aims To determine when patients are at high risk of thromboembolic events, including after major surgery, and to guide timing of thromboprophylaxis. Methods Each IBD patient from Clinical Practice Research Datalink, linked with Hospital Episode Statistics, was matched to up to five non‐IBD patients in this cohort study. We examined their risk of thromboembolism in hospital and within 6 weeks after leaving hospital, with or without undergoing major surgery, and while ambulant. Hazard ratios were estimated using Cox regression, with adjustment for age, sex, body mass index, smoking and history of malignancy or thromboembolism. Results Overall 23 046 IBD patients had a thromboembolic risk 1.74‐times (95% CI = 1.55‐1.96) higher than 106 795 non‐IBD patients. Among ambulant patients, the thromboembolic risk was raised during acute (hazard ratio = 3.94, 2.79‐5.57) or chronic disease activity (3.97, 2.90‐5.45) but their absolute risk remained below 5/1000 person‐years. The hazard ratio for thromboembolism among in‐patients not undergoing major surgery was 1.13 (0.63‐2.02), compared to 2.43 (1.20‐4.92) among surgical patients, with a near doubling of absolute risk associated with surgery (59.5/1000 person‐years, compared with 31.1 without surgery). The absolute risk remained elevated within 6 weeks after leaving hospital (18.6/1000 person‐years in IBD patients after surgery). Conclusions IBD patients are at an increased risk of venous thromboembolism. Absolute risks are raised during active disease, when in hospital, and after leaving hospital following major surgery.

show abstract

Section: Discussionmentioning

confidence: 62%

The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity

Chu

Grainge

Card

2018

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

“…An open‐labeled study comparing the two drugs did not show any significant difference in outcome, and this was confirmed in the CONSTRUCT study . Therefore, the choice of treatment is based on factors such as local availability, cost of therapy, and physician preference, whether patients have been unsuccessfully treated with thiopurines previously . Currently, there are no data for other biologic agents such as adalimumab, golimumab, and vedolizumab, and the general consensus is that these drugs do not act rapidly enough to be effective in this setting.…”

Section: Resultsmentioning

confidence: 93%

“…63 Therefore, the choice of treatment is based on factors such as local availability, cost of therapy, and physician preference, whether patients have been unsuccessfully treated with thiopurines previously. 64 Currently, there are no data for other biologic agents such as adalimumab, golimumab, and vedolizumab, and the general consensus is that these drugs do not act rapidly enough to be effective in this setting. Surgery remains a reasonable and cost-effective option, particularly in many parts of Asia.…”

Section: Statementmentioning

confidence: 99%

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

Ooi

Hilmi

Banerjee

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

The Asia–Pacific Working Group on Inflammatory Bowel Disease was established in Cebu, Philippines, under the auspices of the Asia–Pacific Association of Gastroenterology with the goal of improving inflammatory bowel disease care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in conjunction with conventional treatments for ulcerative colitis and Crohn's disease in Asia. These statements also address how pharmacogenetics influences the treatments of ulcerative colitis and Crohn's disease and provides guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of inflammatory bowel disease workgroup employing the modified Delphi process. These statements do not intend to be all‐encompassing, and future revisions are likely as new data continue to emerge.

show abstract

“…Some respondents indicated this regimen was standard practice, but most indicated empirical infliximab dosing according to disease severity, serum C‐reactive protein (CRP) and albumin concentrations and/or serum infliximab concentrations . These practices are inconsistent with current evidence‐based recommendations that do not support these approaches or recommend intensified infliximab dosing regimens for patients with corticosteroid‐refractory acute severe UC . In this article, we review the current literature on the efficacy and safety of an intensified infliximab dosing regimen in acute severe UC based on available pharmacokinetic and clinical data, and synthesise the evidence to propose considerations for a randomised controlled trial designed to compare a dose‐optimisation strategy with a standard of care approach.…”

Section: Introductionmentioning

confidence: 99%

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

Hindryckx

Novak

Casteele

et al. 2017

Aliment Pharmacol Ther

View full text Add to dashboard Cite

show abstract

Review article: acute severe ulcerative colitis – evidence‐based consensus statements

Abstract: SUMMARY BackgroundAcute severe ulcerative colitis (ASUC) is a potentially life-threatening complication of ulcerative colitis.

Cited by 68 publications

References 215 publications

The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity

The risk of venous thromboembolism during and after hospitalisation in patients with inflammatory bowel disease activity

Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia

Review article: dose optimisation of infliximab for acute severe ulcerative colitis

Contact Info

Product

Resources

About